- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04883515
Effects of Oral Glutamine Supplementation on Insulin Resistance and Functional Intestinal Disorders in Obese Patients. (OBEGLUT)
May 17, 2021 updated by: University Hospital, Rouen
Obesity, which has a prevalence at 15% in France, is a major public health concern.
Altered glycemic control and irritable bowel syndrome (IBS) are frequently observed in obese patients and lead to reduce the quality of life.
In the last decades, the role of gut microbiota and intestinal permeability has been underlined in obesity, glycemic control and IBS.
Interestingly, experimental and clinical data show that glutamine, an amino acid, is able to maintain or restore intestinal permeability in different conditions.
We thus hypothesize that oral glutamine supplementation may restore gut barrier function contributing to improve glycemic control and IBS-symptoms.
Our project will thus aim to evaluate the effects of 8 weeks - oral glutamine supplementation on glycemic control and IBS symptoms in obese patients in a blinded randomized controlled trial.
Placebo group will received protein powder.
55 obese patients will enrolled in each arm and will received oral glutamine supplementation or protein powder (10g t.i.d.) during 8 weeks.
Blood and feces samples and intestinal permeability assays will be performed at baseline (w0), after 8 weeks of supplementation (w8) and then after 8 weeks of a wash-out period (w16).
Study Overview
Status
Not yet recruiting
Conditions
Study Type
Interventional
Enrollment (Anticipated)
110
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hélène LELANDAIS, MD
- Phone Number: 9065 +3323288
- Email: helene.lelandaix@chu-rouen.fr
Study Locations
-
-
-
Rouen, France, 76031
- ROUEN university hospital
-
Contact:
- Hélène LELANDAIS, MD
- Phone Number: 9065 +3323288
- Email: helene.lelandais@chu-rouen.fr
-
Principal Investigator:
- Hélène LELANDAIS, MD
-
Sub-Investigator:
- Vanessa FOLOPE, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients aged from 18 to 65 years
- Patient with h grade II or III obesity (body mass index equal or higher than 35 kg/m2)
- Patient with insulino-resistance (fasting glycaemia ≥ 1g/l et < 1.26 g/l)
- Patient with irritable bowel syndrome (Rome IV criteria ≥ 2)
Exclusion Criteria:
- Patient with Known liver insufficiency (prothrombin time < 70%)
- Patient with Known kidney failure (GFR < 60 ml/mn)
- Patient with Known intestinal diseases such as inflammatory bowel diseases
- Vomiting patients (≥ 1/ day) during the last 4 weeks
- Patient Previously received bariatric surgery or digestive surgery
- Patient Using laxatives or protein powder during the 4 last weeks
- On going Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oral glutamine supplementation
patient will receive Oral glutamine supplementation 10 g Ter In Die during 8 weeks
|
patient will receive oral glutamine supplementation 10 g Ter In Die during 8 weeks
Homeostasic model assessment of insulin resistance test will be performed at baseline, Week 8 and Week 16
Functional intestinal disorders will be measured by the IBS severity score and feces consistency by Bristol scale at baseline, Week 8 and Week 16
|
Active Comparator: Oral protein powder supplementation
patient will receive Oral protein powder supplementation10 g Ter In Die during 8 weeks
|
Homeostasic model assessment of insulin resistance test will be performed at baseline, Week 8 and Week 16
Functional intestinal disorders will be measured by the IBS severity score and feces consistency by Bristol scale at baseline, Week 8 and Week 16
patient will receive oral protein powder supplementation10 g Ter In Die during 8 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change between Homeostasic model assessment of insulin resistance test value at baseline and week 8
Time Frame: Week 8
|
Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change between Homeostasic model assessment of insulin resistance test value at baseline and week 16
Time Frame: Week 16
|
Week 16
|
|
Change between Homeostasic model assessment of insulin resistance test value at Week 8 and week 16
Time Frame: week 16
|
week 16
|
|
Change between Irritable Bowel Syndrome (IBS) severity score at baseline and week 8
Time Frame: Week 8
|
Francis score will be used
|
Week 8
|
Change between Irritable Bowel Syndrome (IBS) severity score at baseline and week 16
Time Frame: Week 16
|
Francis score will be used
|
Week 16
|
Change between feces consistency at baseline and week 8
Time Frame: Week 8
|
bristol scale will be used
|
Week 8
|
Change between feces consistency at baseline and week 16
Time Frame: Week 16
|
bristol scale will be used
|
Week 16
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Hélène LELANDAIS, MD, ROUEN university hospital
- Study Director: Moïse COEFFIER, Pr, ROUEN university hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
June 1, 2021
Primary Completion (Anticipated)
September 1, 2024
Study Completion (Anticipated)
September 1, 2024
Study Registration Dates
First Submitted
May 7, 2021
First Submitted That Met QC Criteria
May 7, 2021
First Posted (Actual)
May 12, 2021
Study Record Updates
Last Update Posted (Actual)
May 19, 2021
Last Update Submitted That Met QC Criteria
May 17, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019/0334/HP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuNot yet recruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Oral glutamine supplementation
-
Jesús González de la Aleja TejeraCompleted
-
Istanbul UniversityNestléCompleted
-
Medical Centre LeeuwardenWithdrawnMechanical Ventilation | Length of Stay | Glutamine
-
Hospital General de MexicoUnknownWound Healing | DiabeticMexico
-
Emmaus Medical, Inc.Completed
-
Emmaus Medical, Inc.FDA Office of Orphan Products DevelopmentCompletedSickle Cell Anemia | ThalassemiaUnited States
-
University of Alabama at BirminghamRecruitingTiming of Sodium Intake and Nocturnal Sodium Excretion and Blood Pressure in Obese African AmericansHypertension | Obesity | Salt; Excess | Circadian DysregulationUnited States
-
Milton S. Hershey Medical CenterCompleted
-
Loughborough UniversityActive, not recruitingLipid Metabolism Disorders | Appetitive Behavior | Glucose Metabolism Disorders (Including Diabetes Mellitus)United Kingdom
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnSarcoma | Childhood Malignant Fibrous Histiocytoma of Bone